Payment overview · 2025
General Payments
$2,550.67
89 reported records · 17 companies
Healthcare provider profile · identity verified
Robert Tae Ha, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GARDEN GROVE, CA · NPI 1750302188
Verified facts
What the public records show
CMS Open Payments records show Robert Tae Ha, MD received $2,550.67 in general payments during 2025 across 89 reported records.
Optos, Inc. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Optos, Inc. | Unresolved — no canonical attribution shown | $552.03 | 21.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $352.02 | 13.8% | 9 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $328.65 | 12.9% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $286.02 | 11.2% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $198.81 | 7.8% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $143.25 | 5.6% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $98.77 | 3.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $94.75 | 3.7% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $88.57 | 3.5% | 4 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $65.27 | 2.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.74 | 2.5% | 3 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.36 | 2.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $57.78 | 2.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $49.33 | 1.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $40.26 | 1.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $38.69 | 1.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.37 | 1.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,998.64 | 88 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $552.03 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $328.65 | 20 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $312.42 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $198.81 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $191.75 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $182.85 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $165.10 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $137.90 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $98.77 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $98.77 | 4 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $65.27 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.74 | 3 | 2025 |
Source payment records
|
|||||
| EUFLEXXA Normalized: euflexxa |
Device | Ferring Pharmaceuticals Inc. | $58.36 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $57.78 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $56.65 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $47.95 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.80 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.80 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $40.26 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.94 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $38.69 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.37 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $25.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 139 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 145 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 53 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 100 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 237 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 169 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 61 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 101 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
139 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
237 | 46 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
45 | 40 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
115 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
145 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
169 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 923 | 245 |
| Amlodipine Besylate | Amlodipine Besylate | 787 | 205 |
| Losartan Potassium | Losartan Potassium | 633 | 138 |
| Memantine Hcl | Memantine Hcl | 516 | 82 |
| Omeprazole | Omeprazole | 497 | 144 |
| Meloxicam | Meloxicam | 482 | 106 |
| Metformin Hcl | Metformin Hcl | 448 | 111 |
| Azithromycin | Azithromycin | 386 | 281 |
| Celecoxib | Celecoxib | 378 | 112 |
| Famotidine | Famotidine | 377 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 369 | 94 |
| Gabapentin | Gabapentin | 363 | 77 |
| Vascepa | Icosapent Ethyl | 292 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 275 | 89 |
| Donepezil Hcl | Donepezil Hcl | 268 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 268 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 268 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 56 |
| Linzess | Linaclotide | 237 | 46 |
| Furosemide | Furosemide | 230 | 36 |
| Potassium Chloride | Potassium Chloride | 222 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 219 | 49 |
| Mirtazapine | Mirtazapine | 207 | 34 |
| Eliquis | Apixaban | 202 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 196 | 42 |
| Trazodone Hcl | Trazodone Hcl | 184 | 44 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 183 | 103 |
| Ozempic | Semaglutide | 169 | 43 |
| Montelukast Sodium | Montelukast Sodium | 157 | 44 |
| Alprazolam | Alprazolam | 153 | 57 |
| Januvia | Sitagliptin Phosphate | 147 | 35 |
| Farxiga | Dapagliflozin Propanediol | 145 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 28 |
| Tradjenta | Linagliptin | 141 | 24 |
| Creon | Lipase/Protease/Amylase | 139 | 37 |
| Alendronate Sodium | Alendronate Sodium | 134 | 36 |
| Finasteride | Finasteride | 134 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 64 |
| Metformin Hcl Er | Metformin Hcl | 133 | 42 |
| Memantine Hcl Er | Memantine Hcl | 132 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 132 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 117 | 24 |
| Myrbetriq | Mirabegron | 115 | 23 |
| Simvastatin | Simvastatin | 112 | 26 |
| Megestrol Acetate | Megestrol Acetate | 111 | 46 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 110 | 52 |
| Lidocaine | Lidocaine | 110 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 20 |
| Mupirocin | Mupirocin | 106 | 69 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 104 | 29 |
| Levofloxacin | Levofloxacin | 104 | 89 |
| Quetiapine Fumarate | Quetiapine Fumarate | 104 | 16 |
| Zenpep | Lipase/Protease/Amylase | 101 | 24 |
| Jardiance | Empagliflozin | 100 | 31 |
| Glimepiride | Glimepiride | 99 | 26 |
| Carvedilol | Carvedilol | 98 | 26 |
| Ezetimibe | Ezetimibe | 97 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 27 |
| Olanzapine | Olanzapine | 91 | 14 |
| Temazepam | Temazepam | 90 | 29 |
| Sertraline Hcl | Sertraline Hcl | 85 | 19 |
| Atenolol | Atenolol | 77 | 16 |
| Divalproex Sodium | Divalproex Sodium | 76 | 11 |
| Glipizide Er | Glipizide | 74 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 74 | 13 |
| Latanoprost | Latanoprost | 74 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 21 |
| Ztlido | Lidocaine | 70 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 69 | 11 |
| Dextrose 5%-0.9% Nacl | Dextrose 5 % And 0.9 % Nacl | 65 | 39 |
| Sucralfate | Sucralfate | 65 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 18 |
| Allopurinol | Allopurinol | 61 | 17 |
| Glipizide | Glipizide | 61 | 19 |
| Ketoconazole | Ketoconazole | 61 | 27 |
| Rexulti | Brexpiprazole | 61 | 12 |
| Lovastatin | Lovastatin | 59 | 19 |
| Lisinopril | Lisinopril | 58 | 18 |
| Meclizine Hcl | Meclizine Hcl | 55 | 27 |
| Midodrine Hcl | Midodrine Hcl | 54 | suppressed |
| Gemtesa | Vibegron | 53 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 53 | 15 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 52 | 21 |
| Icosapent Ethyl | Icosapent Ethyl | 52 | 26 |
| Tramadol Hcl | Tramadol Hcl | 50 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 26 |
| Dexlansoprazole Dr | Dexlansoprazole | 46 | 18 |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 16 |
| Prolia | Denosumab | 45 | 40 |
| Risperidone | Risperidone | 45 | suppressed |
| Valsartan | Valsartan | 43 | suppressed |
| Pregabalin | Pregabalin | 42 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | 12 |
| Baclofen | Baclofen | 41 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Lansoprazole | Lansoprazole | 41 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 11 |
| Prednisone | Prednisone | 39 | 26 |
| Clonidine Hcl | Clonidine Hcl | 37 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 11 |
| Mometasone Furoate | Mometasone Furoate | 36 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Telmisartan | Telmisartan | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | 14 |
| Ciclopirox | Ciclopirox | 32 | 18 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Metolazone | Metolazone | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Repaglinide | Repaglinide | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | 15 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 31 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Spironolactone | Spironolactone | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 22 |
| Cephalexin | Cephalexin | 29 | 22 |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | 11 |
| Cyclosporine | Cyclosporine | 24 | 11 |
| Diazepam | Diazepam | 24 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Restasis | Cyclosporine | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 17 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Bicalutamide | Bicalutamide | 20 | suppressed |
| Naproxen | Naproxen | 20 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 20 | 12 |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | 14 |
| Nitroglycerin | Nitroglycerin | 17 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 12 |
| Cilostazol | Cilostazol | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 13 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Thiothixene | Thiothixene | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,550.67 · 89 records | Optos, Inc. | AIRSUPRA, CAPLYTA, CAPVAXIVE, CREON, EUFLEXXA, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, LINZESS, MOUNJARO, OTEZLA, Ozempic, PANCREAZE, REPATHA, REXULTI, Rybelsus, VIBERZI, Veozah, ZENPEP, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error